title: Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.
abstract: BACKGROUND
  Anorexia nervosa is complicated by severe bone loss and clinical fractures. Mechanisms underlying bone loss in adults with anorexia nervosa include increased bone resorption and decreased formation. Estrogen administration has not been shown to prevent bone loss in this population, and to date, there are no approved, effective therapies for this comorbidity.
  
  
  OBJECTIVE
  To determine whether antiresorptive therapy with a bisphosphonate alone or in combination with low-dose transdermal testosterone replacement would increase bone mineral density (BMD) in women with anorexia nervosa.
  
  
  METHODS
  We conducted a12-month, randomized, placebo-controlled study at a clinical research center.
  
  
  METHODS
  Participants included 77 ambulatory women with anorexia nervosa.
  
  
  METHODS
  Subjects were randomized to risedronate 35 mg weekly, low-dose transdermal testosterone replacement therapy, combination therapy or double placebo.
  
  
  METHODS
  BMD at the spine (primary endpoint), hip, and radius and body composition were measured by dual-energy x-ray absorptiometry.
  
  
  RESULTS
  Risedronate increased posteroanterior spine BMD 3%, lateral spine BMD 4%, and hip BMD 2% in women with anorexia nervosa compared with placebo in a 12-month clinical trial. Testosterone administration did not improve BMD but increased lean body mass. There were few side effects associated with either therapy.
  
  
  CONCLUSIONS
  Risedronate administration for 1 yr increased spinal BMD, the primary site of bone loss in women with anorexia nervosa. Low-dose testosterone did not change BMD but increased lean body mass.
authors.affiliation: Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. KKMiller@Partners.org
authors.forename: Karen K
authors.initials: KK
authors.lastname: Miller
authors.forename: Erinne
authors.initials: E
authors.lastname: Meenaghan
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Lawson
authors.forename: Madhusmita
authors.initials: M
authors.lastname: Misra
authors.forename: Suzanne
authors.initials: S
authors.lastname: Gleysteen
authors.forename: David
authors.initials: D
authors.lastname: Schoenfeld
authors.forename: David
authors.initials: D
authors.lastname: Herzog
authors.forename: Anne
authors.initials: A
authors.lastname: Klibanski
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000728:Androgens / Q000008:administration & dosage / Q000627:therapeutic use*; D000856:Anorexia Nervosa / Q000150:complications*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000068296:Risedronic Acid; D013131:Spine / Q000187:drug effects; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D050071:Bone Density Conservation Agents; D013739:Testosterone; D000068296:Risedronic Acid; D012968:Etidronic Acid